Archive

Palbociclib (CDK4/6 Inhibitor)-Related Uveitis With Cystoid Macular Edema in Metastatic Breast Cancer: A Case Report and Review of Small-Molecule Targeted Drug-Related Uveitis

Palbociclib is now standard in metastatic breast cancer; bilateral uveitis with macular edema is a sight-threatening toxicity to recognise early and refer, not dismiss as conjunctivitis.

Oncology · Cureus · 24h

Follicular Mucinosis of the Eyebrow as a Cutaneous Clue to Classic Hodgkin Lymphoma: A Case Report

Skin biopsy showed follicular mucinosis (Alcian blue positive); lymph node biopsy confirmed classic Hodgkin lymphoma, nodular sclerosis. ABVD chemotherapy produced complete metabolic response on PET/CT with hair regrowth

Oncology · Cureus · 2d

Max oncology inpatient revenue falls after chemotherapy drug discontinuation for CGHS patients

CGHS rate revisions and chemo discontinuation are shifting where your CGHS oncology patients can be treated — check referral pathways and out-of-pocket costs before the next admission.

Oncology · ETHealthworld · 2d

Basophils inhibit early lung metastasis by suppressing regulatory T cells.

Mouse data only, but it reframes basophils as antitumour immune regulators — a possible biomarker or target if you follow early metastatic seeding.

Oncology · Nature cancer · 2d

A live biotherapeutic product for adult allogeneic hematopoietic cell transplantation recipients: a partially randomized, placebo-controlled phase 1b trial.

Phase 1b only — no efficacy signal yet, but if colonisation protects the gut barrier, it could change how you counsel allo-HCT patients on infection risk.

Oncology · Nature Medicine · 2d

Regulatable membrane-bound IL-15 engineered TIL cell therapy for immune checkpoint inhibitor-resistant advanced melanoma: pooled analysis of phase 1 and 1/2 trials.

Engineered TILs that avoid systemic IL-2 could make cell therapy tolerable for checkpoint-resistant melanoma, sparing patients high-dose IL-2 toxicity.

Oncology · Nature Medicine · 2d

FDA Provides Clarity to Support Cell and Gene Therapy Development and Quality

Potency assays are the usual bottleneck for CAR-T and gene therapy approvals; clearer FDA expectations mean faster access to these therapies for your patients.

Oncology · FDA — Press Announcements · 3d

Archive-Recorded Volume Change in Matched Renal Target Lesions: A Secondary Analysis of Public Pediatric Oncology Annotations

Highlights that public pediatric trial archives can support longitudinal lesion-volume tracking only if lesion identity and exam selection are rigorously matched — a caution for anyone mining imaging archives.

Oncology · Cureus · 3d

Feasibility of Developing a Music Therapy Program for Radiation Oncology Outpatients at a Large Canadian Cancer Center: A Cross-Sectional Survey

95.0% considered music therapy relevant to radiation oncology patients and 87.5% supported a pilot program, yet only 21.3% saw it as an evidence-based therapy delivered by a trained professional and 5.0% knew the SIO-ASCO guideline.

Oncology · Cureus · 3d

Myeloid-derived TGFβ1 and oncostatin M establish two distinct stromal niches controlling late and hybrid EMT states.

Two myeloid signals, TGFβ1 and oncostatin M, steer tumours into distinct hybrid EMT states — a mechanistic handle on the plasticity that drives therapy resistance.

Oncology · Nature cancer · 3d

Neoadjuvant botensilimab with or without balstilimab in pMMR and dMMR colon cancer: the phase 2 UNICORN trial.

If an Fc-enhanced anti-CTLA-4 antibody shrinks pMMR colon tumours preoperatively, the mismatch-repair barrier to immunotherapy in your resectable patients may not be absolute.

Oncology · Nature Medicine · 3d

Comparative Cost-Effectiveness of Prostate-Specific Membrane Antigen Positron Emission Tomography Agents and Conventional Imaging for Initial Diagnosis of Prostate Cancer in the United States

PSMA PET staging is more sensitive than conventional imaging but costs more; this analysis quantifies whether that trade-off holds for your newly diagnosed patients.

Oncology · Cureus · 4d

Reduced Oxycodone Efficacy Associated With Carbamazepine Use in a Patient With Advanced Cholangiocarcinoma

Before escalating opioids in cancer pain, check for enzyme-inducing co-medications like carbamazepine — the interaction, not the disease, may be driving the pain.

Oncology · Cureus · 4d

Assam signs Rs 600 crore deal for India's first state-run proton therapy centre

Proton therapy spares surrounding tissue better than photons, so Northeast patients needing skull-base, paediatric or re-irradiation cases may no longer travel abroad or to metros.

Oncology · ETHealthworld · 4d

Head and neck cancer burden attributable to tobacco use in India: National and region-wise estimates.

Quantifies how much head and neck cancer in your catchment is tobacco-attributable, giving state-level numbers to anchor cessation counselling and screening arguments.

Oncology · Indian journal of medical research · 4d

Circulating biomarkers for diagnosis of doxorubicin-induced cardiotoxicity in breast cancer patients: A prospective observational study.

LVEF fell from 65.00±2.17% to 59.50±5.47% and GLS from -19.04±1.87% to -15.37±1.79%. GLS associated with hs-Troponin I (P=0.04), IL-33 (P=0.04) and miR126-3p (P=0.006); LVEF with hs-Troponin I (P=0.03) and IL-33 (P=0.04).

Oncology · Indian journal of medical research · 4d

Analysis of Factors Associated With Hemorrhage Post-radiotherapy for Brain Metastasis: A Population-Based Study

Quantifies which metastasis and treatment factors predict post-RT intracranial hemorrhage, helping you decide surveillance imaging intensity and counsel patients on bleeding risk.

Oncology · Cureus · 5d

Outcomes Following Breast-Conserving Surgery for Positive Radial Margins: A Five-Year Longitudinal Study

Quantifies residual disease and five-year outcomes after re-excision for positive radial margins, informing how aggressively you counsel patients before a second surgery.

Oncology · Cureus · 5d

Surgical De-escalation After Neoadjuvant Immunotherapy for Cutaneous Squamous Cell Carcinoma: Oncological Safety and Reconstructive Consequences

Before shrinking surgery after neoadjuvant PD-1 blockade in resectable cSCC, know that the evidence for omitting or reducing local treatment is still unresolved.

Oncology · Cureus · 5d

Consolidative Prostate Radiotherapy in de Novo Oligometastatic Mixed Small Cell Neuroendocrine Prostate Cancer: A Case Report

Rare mixed small-cell neuroendocrine prostate cancer can respond to consolidative radiotherapy to the primary even with oligometastases; consider tissue diagnosis when PSA is low relative to burden.

Oncology · Cureus · 6d

Intraperitoneal Small Round Cell Tumor Suggestive of Extraskeletal Ewing Sarcoma in an Eight-Year-Old Girl: Conversion to Resection and Adjuvant Volumetric Modulated Arc Therapy

Shows that a vessel-encasing paediatric EES can be converted to resectable disease and consolidated with VMAT, a pathway worth considering before calling such masses inoperable.

Oncology · Cureus · 6d

From Remission to Complication: Hemophagocytic Lymphohistiocytosis and Avascular Necrosis During Brentuximab Therapy in Hodgkin Lymphoma

On brentuximab for relapsed Hodgkin's, watch for HLH and avascular necrosis — rare but treatable complications that can mimic progression or infection.

Oncology · Cureus · 6d

Epidermal Growth Factor Receptor (EGFR) Mutations in Rare Histological Subtypes of Ovarian Cancer

If rare ovarian subtypes carry actionable EGFR mutations, testing beyond high-grade serous histology could open targeted options for patients currently managed on generic chemotherapy.

Oncology · Cureus · 6d

ANO6-mediated trogocytosis of cancer-associated fibroblasts promotes pancreatic cancer cell growth and immune suppression.

Explains how pancreatic tumours feed themselves through CAF trogocytosis of blood-borne lipids, pointing at ANO6 and stromal lipid handling as targets in a cancer where vessels are scarce.

Oncology · Nature cancer · 6d

BAZ2A-induced epigenetic states in cancer cells fuel palmitate accumulation in the tumor microenvironment driving CAR-T cell exhaustion.

Explains why CD70 CAR-T fails in solid tumours: tumour BAZ2A drives palmitate buildup that exhausts T cells, a targetable resistance axis.

Oncology · Nature cancer · 6d

GALE is a tumor-intrinsic checkpoint of Vγ9Vδ2 T cell-mediated killing.

If GALE loss sensitises tumours to gamma-delta T cells, it becomes a biomarker and target for off-the-shelf cell therapy trials your patients may be offered.

Oncology · Nature cancer · 6d

Efficacy and Safety of DoceAqualip in a Patient With Metastatic Triple-Negative Breast Cancer Beyond 40 Cycles: A Case Report

A single case of a docetaxel formulation tolerated past 40 cycles in metastatic TNBC is hypothesis-generating only; it does not yet justify changing your regimen or supportive-care plan.

Oncology · Cureus · 7d

An agentic AI system enhances clinical detection of immune-related adverse events in a multi-phase validation study.

Up to 40% of checkpoint-inhibitor patients develop irAEs that chart review misses; an AI-plus-human workflow could catch them earlier, though you still verify every flag.

Oncology · Nature cancer · 7d

5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial.

Confirms that PET-response-guided omission of chemotherapy preserves 5-year outcomes in HER2-positive early breast cancer, supporting de-escalation in selected patients.

Oncology · Nature Medicine · 7d

A genome‑wide screen in E. coli reveals metabolic adaptations that enhance intratumoral fitness and bacterial cancer therapy efficacy.

Deleting nonglucose phosphotransferase systems improved tumour colonisation in E. coli — a design rule for the bacterial cancer therapies now entering early-phase trials.

Oncology · Nature cancer · 7d

Insights into early-onset colorectal cancer from a single-nucleus RNA-seq atlas of colorectal cancer across the age continuum.

Early-onset CRC appears biologically distinct at the single-cell level, which may eventually justify different treatment or surveillance for patients diagnosed under 50.

Oncology · Nature Medicine · 7d

Combining locoregional treatments and immunotherapies in patients with unresectable hepatocellular carcinoma.

Five phase III trials showed improvements in progression-free survival and objective response rates with ICI plus transarterial chemoembolization. Early-phase and real-world data support ICI with radioembolization or radiotherapy in focal disease and portal vein tumour thrombosis.

Oncology · Nature reviews. Clinical oncology · 8d

Overcoming Barriers in the Treatment of Limited-Stage Small Cell Lung Cancer With a Focus on Low- and Middle-Income Countries: A Narrative Review

If you treat SCLC in India, this maps the real constraints — late staging, radiotherapy access, chemo logistics — that decide whether concurrent chemoradiation is actually deliverable.

Oncology · Cureus · 9d

Impact of Demographic and Socioeconomic Factors on Survival Associated With Androgen Receptor Pathway Inhibitor Use in Metastatic Prostate Cancer: An Analysis of the Surveillance, Epidemiology, and End Results (SEER)-Medicare Database

SEER-Medicare data show ARPI survival gains in metastatic prostate cancer are uneven across demographic and socioeconomic groups — check whether your eligible patients are actually being offered it.

Oncology · Cureus · 9d

Obesity and Cancer Risk in Young Adults in Korea : A Nationwide Health Screening Cohort Study.

Ten-year cumulative cancer incidence rose from 1.84% in normal-weight to 2.24% in class I and 2.62% in class II obesity; absolute risk differences 0.40% and 0.78%. Highest incidence for thyroid, endometrial and ovarian cancer.

Oncology · Annals · 9d

AI model uses face photos to estimate biological age, predict survival risk in cancer patients

A face photo-derived biological age score predicted survival in cancer patients; it is not validated for treatment decisions, so treat it as a research triage signal only.

Oncology · ETHealthworld · 10d

Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.

A first-in-class EGFR/HER3 bispecific ADC offers a new mechanism for heavily pretreated HR+/HER2- disease, where endocrine and chemotherapy options are largely exhausted.

Oncology · Lancet · 10d

Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.

If sac-TMT beats physician's choice after platinum and immunotherapy, it gives your post-progression endometrial cancer patients a TROP2-directed option where few exist.

Oncology · Lancet · 10d

Neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable non-small-cell lung cancer: the phase 2 MDT-BRIDGE trial.

Adds a perioperative durvalumab pathway for borderline-resectable NSCLC, with MDT triage deciding who proceeds to surgery versus CRT plus consolidation.

Oncology · Nature Medicine · 10d

Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.

If this HER3 ADC beats chemotherapy after TKI failure, it gives your EGFR-mutated patients a new option before or alongside platinum doublets.

Oncology · Lancet · 10d